The FDA has approved Prezista (darunavir tablet, from Tibotec) for use in combination with ritonavir for treatment-naïve adults with HIV-1. In the randomized, open-label ARTEMIS study, the Prezista/ritonavir combination produced similar rates of undetectable HIV viral loads and changes in CD4+ cell counts as compared to lopinavir/ritonavir in patients not previously treated for HIV-1.>

Prezista will be available in a 400mg dosage strength in November 2008 in addition to the 600mg tablets already offered. Tibotec will discontinue the 300mg dosage strength due to decreased demand.

Prezista a protease inhibitor, is already approved in combination with other antiretroviral agents for treating HIV in antiretroviral treatment-experienced adults.

For more information call (877) REACH-TT or visit www.www.prezista.com.